Don't Gamble On Antibodies
Every mis-characterized and unvalidated antibody is a coin flip with your reputation, funding and publication record on the line.
Are you taking chances with your research?
Tap Coin To Flip
Are you taking chances with your research?
The Scale Of The Antibody Crisis
About 50% of the 6 million commercial antibodies fail basic characterization, driving billions in wasted experiments and irreproducible data (1-4).
Very few antibody suppliers perform genetic knockout/knockdown controls, orthogonal strategies, spike-in or competition assays, and biological validation using appropriate positive and negative samples.
Only 1-2%
Commercial antibodies fully comply with comprehensive, multi-pillar validation guidelines (5).
We Are
The 1-2%
In a market flooded with under‑validated reagents, we are the statistical outlier – in a good way. As the original source, we combine a robust catalog with deep custom capabilities, helping you access the right antibody for your application.
Most vendors sell a vial, we help protect your experiments so you avoid the coin‑flip.
Farm‑to‑Bench™ supply
Direct control from source to final product protects lot continuity, reagent quality, and long-term availability across grants, publications, collaborations, and expanding research programs. Expert scientific support helps resolve issues quickly and keep studies moving.
Chosen by Researchers
Bethyl, a Fortis company, received the 2021 CiteAb Researchers’ Choice Award, reflecting independent researcher preference for antibody performance and support.
Proven in the literature
Researchers have cited Bethyl antibodies in more than 30,000 peer-reviewed publications, demonstrating confidence across diverse applications and study areas.
Deep characterization data
Fortis reagents are characterized using biochemical and application-relevant biological assays to confirm specificity and performance consistency before release.
Sequence‑Defined identity
Recombinant antibodies, antigens, and VHHs are manufactured in‑house, ensuring consistent sourcing, controlled production, and reliable performance across lots and programs.
Six‑Pillar validation
Antibodies are validated using the established Pillars of Antibody Validation and tested in application‑relevant assays, such as WB, IF/ICC, IHC, IP and ELISA), with each new lot evaluated to ensure consistent performance.
Find the Right Antibody Strategy for Your Research
Whether you need a validated catalog antibody for an established target or a custom reagent for novel biology, Fortis helps academic labs choose the right path for your studies.
Select your research challenge to see the best-fit solution, supporting proof, and next steps.
From Coin Toss to Defendable Data
We protect your most expensive experiments from antibody-driven failure.
We combine rigorous validation, in-house manufacturing, broad catalog depth, custom development, and Farm-to-Bench supply continuity to help you generate data that stands up to review, replication, and long-term use.
Choose antibodies built for results you can defend.
Indicate how you would like the Antibody Solutions team to help you improve reproducibility.
- Baker, M. (2016). 1,500 scientists lift the lid on reproducibility. Nature, 533(7604), 452–454.
- National Academies of Sciences, Engineering, and Medicine. (2019). Reproducibility and replicability in science. National Academies Press.
- Kahn, R. A., & Laflamme, C. (2024). Antibody characterization is critical to enhance reproducibility in biomedical research. eLife, 13, e100211.
- Biddle, M., Stylianou, P., et al. (2024). Improving the integrity and reproducibility of research that uses antibodies: A technical, data sharing, behavioral and policy challenge. mAbs, 16(1), 2323706.
- Ayoubi, R., Laflamme, C., Shlaifer, I., et al. (2023). Scaling of an antibody validation procedure enables quantification of antibody performance at the proteome scale. eLife, 12, e91645.
